CHRNA2 — Cholinergic Receptor Nicotinic Alpha 2

CHRNA2 — Cholinergic Receptor Nicotinic Alpha 2

Introduction

CHRNA2 (Cholinergic Receptor Nicotinic Alpha 2) encodes the α2 subunit of the nicotinic acetylcholine receptor (nAChR) family. This ligand-gated ion channel subunit forms heteromeric receptors critical for fast cholinergic synaptic transmission throughout the peripheral and central nervous systems. CHRNA2 has been implicated in epilepsy, autonomic dysfunction, and potentially in neurodegenerative diseases including Alzheimer's Disease and Parkinson's Disease. This page covers the gene's structure, function, disease associations, and therapeutic implications.

CHRNA2 — Cholinergic Receptor Nicotinic Alpha 2

Introduction

CHRNA2 (Cholinergic Receptor Nicotinic Alpha 2) encodes the α2 subunit of the nicotinic acetylcholine receptor (nAChR) family. This ligand-gated ion channel subunit forms heteromeric receptors critical for fast cholinergic synaptic transmission throughout the peripheral and central nervous systems. CHRNA2 has been implicated in epilepsy, autonomic dysfunction, and potentially in neurodegenerative diseases including Alzheimer's Disease and Parkinson's Disease. This page covers the gene's structure, function, disease associations, and therapeutic implications.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Cholinergic Receptor Nicotinic Alpha 2</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>CHRNA2</td></tr>
<tr><td><strong>Full Name</strong></td><td>Cholinergic receptor nicotinic alpha 2 subunit</td></tr>
<tr><td><strong>Chromosome</strong></td><td>8p21</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[1135](https://www.ncbi.nlm.nih.gov/gene/1135)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[104500](https://www.omim.org/entry/104500)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000120288</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P43681](https://www.uniprot.org/uniprotkb/P43681)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Epilepsy](/diseases/epilepsy), [Autonomic dysfunction](/diseases/autonomic-dysfunction), [AD](/diseases/alzheimers-disease), [PD](/diseases/parkinsons-disease)</td></tr>
</table>
</div>

Overview

CHRNA2 is a member of the Cys-loop receptor superfamily, which also includes GABAₐ, glycine, and 5-HT3 receptors. The alpha2 subunit typically combines with beta2 or beta4 subunits to form functional heteromeric nAChRs. These receptors are expressed in both the central and peripheral nervous systems, where they mediate fast synaptic transmission and modulate neuronal excitability.

Key characteristics:

• Ligand-gated ion channel (ionotropic receptor)
• Permeable to Na+, K+, and Ca2+
• Activated by acetylcholine (ACh) and nicotine
• Subject to rapid desensitization

Protein Structure

Overall Architecture

The nAChR is a pentameric ligand-gated ion channel. CHRNA2 contributes to the formation of:

• Extracellular N-terminal domain: Contains the acetylcholine binding site
• Transmembrane domain: Four α-helices (M1-M4) forming the ion channel pore
• Intracellular loop: Between M3 and M4, contains phosphorylation sites
• Extracellular C-terminal domain

Acetylcholine Binding Site

The ACh binding site is located at the interface between adjacent subunits:

• Principal binding component: C-loop of the α subunit (CHRNA2)
• Complementary component: Adjacent non-α subunit (β2/β4)

• Aromatic residues (Trp, Tyr, Phe) for ACh binding
• Disulfide bond at the tip of the C-loop (characteristic of Cys-loop receptors)
• Glycosylation sites for proper folding

Ion Channel Pore

The channel pore is formed by the M2 transmembrane helices:

• Ring of negatively charged residues at the extracellular entrance (selectivity filter)
• Hydrophobic gate region
• Intracellular entrance with additional regulatory sites

Receptor Subtypes

CHRNA2 forms heteromeric nAChRs with specific subunit compositions:

| Receptor | Stoichiometry | Expression | Function |
|----------|---------------|------------|----------|
| α2β2 | α2:β2 = 2:3 | CNS, autonomic ganglia | Major CNS receptor |
| α2β4 | α2:β4 = 2:3 | Autonomic ganglia, brain | Peripheral, some CNS |
| α2α5β2 | α2:α5:β2 = 1:1:3 | CNS | High Ca²⁺ permeability |

The α5 subunit inclusion (α2α5β2) significantly increases Ca²⁺ permeability, which has important implications for neuronal signaling and disease processes.

Expression Pattern

CHRNA2 demonstrates unique expression patterns:

Central Nervous System

• Hippocampus: CA1-CA3 pyramidal cells, dentate gyrus granule cells
• Cortex: Layer 2/3 interneurons
• Thalamus: Relay neurons
• Brainstem: Motor and sensory nuclei
• Cerebellum: Molecular layer interneurons

Peripheral Nervous System

• Autonomic ganglia: Sympathetic and parasympathetic neurons
• Enteric nervous system: Myenteric and submucosal plexus

Glial Expression

• Astrocytes (moderate)
• Microglia (low, inducible)

Role in Neuronal Signaling

Synaptic Transmission

CHRNA2-containing nAChRs mediate:

Calcium Signaling

The Ca²⁺ permeability of α2β2* and especially α2α5β2 receptors enables:

• Activation of intracellular Ca²⁺ signaling cascades
• Synaptic plasticity mechanisms
• Gene transcription via Ca²⁺-dependent pathways

Neuromodulation

CHRNA2 receptors modulate:

• Dopaminergic signaling in the striatum
• GABAergic inhibition in cortical circuits
• Glutamatergic transmission

Role in Alzheimer's Disease

Cholinergic Hypothesis Connection

The cholinergic hypothesis of AD proposes that loss of cholinergic neurons contributes to cognitive decline. CHRNA2 is relevant because:

Amyloid Interaction

• Aβ directly interacts with nAChRs
• Aβ binding may dysregulate α2-containing receptor function
• Nicotinic stimulation may reduce Aβ-induced toxicity

Tau Pathology

nAChR signaling intersects with tau pathology:

• PKC and CaMKII pathways modulate tau phosphorylation
• Cholinergic dysfunction may exacerbate tau pathology

Role in Parkinson's Disease

Dopaminergic Modulation

CHRNA2 receptors influence dopaminergic function:

• Nigrostriatal pathway modulation
• Mesolimbic and mesocortical circuits
• Motor control via basal ganglia circuits

Nicotine and PD

Epidemiological studies show:

• Smoking is associated with reduced PD risk
• Nicotine may protect dopaminergic neurons
• α4/α6-containing receptors (not α2) primarily mediate this effect

Autonomic Dysfunction

CHRNA2 mutations cause autonomic disorders:

• Dysautonomia in epilepsy patients
• Orthostatic hypotension
• Thermoregulatory dysfunction

Disease Associations

Epilepsy

CHRNA2 mutations cause autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE):

• Phenotype: Brief seizures during sleep
• Mechanism: Gain-of-function mutations increase channel activity
• Treatment: Carbamazepine (Na⁺ channel blocker)

Autonomic Dysfunction

CHRNA2 mutations are associated with:

• Autonomic seizures
• Central hypoventilation
• Cardiac arrhythmias

Alzheimer's Disease (Potential)

• Altered nAChR expression in AD brains
• CHRNA2 polymorphism associations with AD risk
• Therapeutic targeting of nAChRs

Parkinson's Disease (Potential)

• nAChR expression changes in PD
• Nicotine protection studies
• CHRNA2 role in autonomic symptoms

Therapeutic Implications

Drug Targets

Challenges

• Receptor desensitization
• Side effects (nausea, cardiovascular)
• Lack of subtype selectivity

Research Directions

• Subtype-selective agonists
• Brain-penetrant compounds
• Disease-modifying approaches

Key Publications

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Epilepsy](/diseases/epilepsy)
• [Acetylcholine Signaling](/mechanisms/acetylcholine-signaling)
• [Nicotinic Receptors](/mechanisms/nicotinic-receptor-signaling)
• [Cholinergic System](/mechanisms/cholinergic-system)
• [Synaptic Transmission](/mechanisms/synaptic-transmission)
• [Calcium Signaling](/mechanisms/calcium-signaling)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving CHRNA2 — Cholinergic Receptor Nicotinic Alpha 2 discovered through SciDEX knowledge graph analysis: